-
-
Chronic toxicity study – OECD 452

Chronic toxicity study – OECD 452

Technique(s)
Category:
Sector of activity
Tag:
Expertise

Biological test

Method

OECD 452

Description

Chronic toxicity testing assesses the biological effects of repeated exposure to a chemical substance over a prolonged period. Unlike acute toxicity testing, it examines sublethal manifestations that can impact health in the medium or long term: reproductive impairment, metabolic effects, organ damage, abnormal behavior, etc. This test is a key regulatory requirement under REACH, the CLP Regulation, and substance safety assessment processes.

Objective of the analysis

The purpose of this test is to:

  • Determine systemic toxic effects during prolonged exposure (often 90 days or more)
  • Identify the no observed adverse effect thresholds (NOAEL) and with observed adverse effect thresholds (LOAEL)
  • Provide data for long-term risk assessment
  • Meet regulatory requirements for the registration or evaluation of chemical substances

OECD 452 Methodology

OECD Guideline is generally carried out in vivo on rodents (rats or mice), exposed daily to the test substance orally, dermal or inhaled. The minimum recommended duration is 90 days, but longer protocols can be implemented depending on specific requirements.

The parameters evaluated include:

  • Food and water consumption
  • Body weight and behavior
  • Hematological and biochemical parameters
  • Histopathological examination of target organs
  • Reproductive, developmental or immunotoxicity data (if required)

Sectors and applications concerned

  • Cosmetics : long-term safety of an active ingredient or preservative
  • Chemistry : REACH registration, CMR substance notifications
  • Pharmaceutical / biotechnology : preclinical evaluation
  • Agrochemistry : regulatory studies for active substances

Why use YesWeLab?

YesWeLab connects you to specialized regulatory laboratories, approved to carry out chronic toxicology studies in accordance with OECD standard 452. Our partners have animal platforms under Good Laboratory Practices (GLP), integrated histopathology capabilities, and behavioral and metabolic monitoring devices.

Our team supports you from the definition of the experimental protocol to the interpretation of the results for your REACH, CLP procedures, or for specific customer or regulatory authority requirements.

See also:

Other analyses we perform

Back to top